Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.40 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.36 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27087525 | 0.92 | ALK (0.41) | ALKEML4SRPK2SRPK1KDR | |
| SCHEMBL30009833 | 0.90 | ALK (0.40) | ALK | |
| SCHEMBL27087547 | 0.90 | ALK (0.36) | ALKEML4 | |
| SCHEMBL30010134 | 0.86 | ALK (0.42) | ALKEML4SRPK2SRPK1KDR | |
| SCHEMBL29940669 | 0.86 | ALK (0.48) | ALK | |
| SCHEMBL27087527 | 0.86 | ALK (0.48) | ALK | |
| SCHEMBL28913313 | 0.83 | ALK (0.56) | ALKEML4SRPK2SRPK1KDR | |
| SCHEMBL30009875 | 0.83 | ALK (0.53) | ALKEML4SRPK2SRPK1KDR | |
| SCHEMBL27087617 | 0.83 | ALK (0.38) | ALKEML4SRPK2SRPK1 | |
| SCHEMBL30009523 | 0.79 | ALK (0.55) | ALKEML4SRPK2SRPK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246927-A1 | COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2022237813-A1 | COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛世泰科生物医药技术(苏州)有限公司 | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246927-A1 | COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | ALK, ACVR1, ALKBH3 | ALK 1/4885EML4 1647/4885SRPK2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.